Krystal Biotech Shines Bright: RBC Capital Markets Sees Major Upside

Well, isn't this some encouraging news for Krystal Biotech (KRYS)! RBC Capital Markets has officially jumped into the fray, kicking off their coverage of the gene therapy company with a rather enthusiastic 'Outperform' rating. It's clear that analyst Lisa Walter and her team see significant runway ahead, setting a pretty ambitious $400 price target for the stock, effective Friday, August 14, 2026.

Now, a big part of this bullish sentiment, it seems, rests squarely on the shoulders of Vyjuvek, Krystal's lead product. This innovative therapy is designed to treat dystrophic epidermolysis bullosa, a truly devastating and rare blistering skin condition. The market traction for Vyjuvek has been nothing short of impressive; it's already projected to capture over 60% of the total addressable market for DEB right here in the U.S. What's more, RBC anticipates this therapy could hit peak sales of a whopping $1 billion by 2033. And it's not just a domestic story, mind you, with an overseas launch set to begin as early as Q3 2025, suggesting a broader global impact is on the horizon.

But wait, there's another compelling chapter to Krystal's story: their experimental therapy, KB801. This treatment is aimed at neurotrophic keratitis, another rare eye disorder, and the projections here are even more eye-popping, if you'll excuse the pun. RBC believes KB801 could potentially achieve peak sales of $2.1 billion as early as 2030. Of course, the analyst team, quite rightly, injects a note of caution, stating they are "cautiously optimistic" about KB801. And that makes sense, given that we're currently relying on just one positive clinical data point. Still, with near-term readouts anticipated in the second half of 2026 and a pivotal readout expected early in 2027, there's certainly a lot to look forward to on this front. These upcoming milestones could very well validate that initial optimism.

All in all, RBC Capital Markets' initiation paints a rather bright picture for Krystal Biotech. Between the established potential of Vyjuvek and the significant, albeit early-stage, promise of KB801, it’s clear why the firm views KRYS as a compelling investment opportunity. Investors will undoubtedly be watching closely as Krystal continues to advance its pipeline and expand its market reach.